Page last updated: 2024-08-23

pirfenidone and Disease Exacerbation

pirfenidone has been researched along with Disease Exacerbation in 141 studies

Research

Studies (141)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (1.42)	29.6817
2010's	109 (77.30)	24.3611
2020's	30 (21.28)	2.80

Authors

Authors	Studies
Kang, J; Song, JW	1
Anevlavis, S; Archontogeorgis, K; Bonelis, K; Froudarakis, M; Ntolios, P; Paxinou, N; Steiropoulos, P; Voulgaris, A	1
Hachisu, Y; Hisada, T; Koga, Y; Kouno, S; Maeno, T; Nakagawa, J; Saito, Y; Sawada, Y; Shin, Y; Sunaga, N; Takehara, K; Umetsu, K; Utsugi, M; Wakamatsu, I; Yatomi, M; Yoshimi, S	1
Baba, T; Ikeda, S; Iwasawa, T; Katano, T; Kato, T; Kitamura, H; Oda, T; Ogura, T; Okuda, R; Sekine, A; Shintani, R; Tabata, E; Takemura, T; Yamakawa, H	1
Crooks, JL; Fernández Pérez, ER; Fier, K; Groshong, SD; Humphries, SM; Koelsch, TL; Lynch, DA; Mohning, MP; Solomon, JJ; Swigris, JJ	1
Aguilar-Medina, S; Alva-Lopez, LF; Cazzola, M; Domínguez-Arellano, S; Escobar-Alvarado, JC; Falfán-Valencia, R; Matera, MG; Montiel-Lopez, F; Olaya-López, E; Pérez-Rubio, G; Poo, JL; Ramírez-Venegas, A; Sansores, RH; Zavaleta-Martínez, EO	1
Glassberg, MK	1
Distler, J; Fischer, A	1
Chaudhuri, N; Kahn, N; Kreuter, M; Müller, V; Somogyi, V; Torrisi, SE	1
Bocchino, M; Boschetto, P; Casillo, V; Cerri, S; Ciervo, A; Flacco, ME; Luppi, F; Manno, M; Manzoli, L; Stendardo, M	1
Kolb, MR; Wongkarnjana, A; Yanagihara, T	1
Bartley, K; Bondue, B; Compere, C; Dahlqvist, C; Gusbin, N; Kirchgaessler, KU; Lee, YC; Maddens, S; Schlesser, M; Slabbynck, H; Wuyts, WA	1
Eichinger, M; Heussel, CP; Kahn, N; Kreuter, M; Lars, K; Palmucci, S; Polke, M; Sambataro, D; Sambataro, FM; Sambataro, G; Sarmand, N; Torrisi, SE; Vancheri, C; Wälscher, J	1
Imanishi, N; Kanayama, M; Kuroda, K; Kuwata, T; Matsumiya, H; Mori, M; Shinohara, S; Taira, A; Tanaka, F; Yoneda, K	1
Chiba, H; Ikeda, K; Kuronuma, K; Mori, Y; Nishikiori, H; Otsuka, M; Takahashi, H; Umeda, Y; Yoshikawa, T	1
Higo, H; Ichikawa, H; Itano, J; Kajimoto, K; Kanehiro, A; Kayatani, H; Kiura, K; Maeda, Y; Miyahara, N; Oda, N; Senoo, S; Shibayama, T; Taniguchi, A; Tanimoto, Y; Watanabe, H	1
Aokage, K; Ishii, G; Miyoshi, T; Sekihara, K; Tane, K; Tsuboi, M	1
Calvello, M; Cerri, S; Donatelli, P; Iovene, B; Lo Greco, E; Luppi, F; Pavone, M; Richeldi, L; Sgalla, G; Vancheri, A; Vancheri, C; Varone, F	1
Białas, AJ; Buchczyk, M; Gomółka, P; Górska, K; Jagielska-Len, H; Jarzemska, A; Jassem, E; Jastrzębski, D; Kania, A; Koprowski, M; Krenke, R; Kuś, J; Lewandowska, K; Majewski, S; Martusewicz-Boros, MM; Piotrowski, WJ; Roszkowski-Śliż, K; Siemińska, A; Sobiecka, M; Szewczyk, K; Sładek, K; Tomczak, M; Tomkowski, W; Wiatr, E; Ziora, D; Żołnowska, B	1
Boulate, D; Crutu, A; Dauriat, G; Dolidon, S; Fabre, D; Fadel, E; Feuillet, S; Florea, V; Gazengel, P; Hanna, A; Le Pavec, J; Mercier, O; Mitilian, D; Mussot, S; Pradere, P	1
Franciosa, C; Richeldi, L; Sgalla, G; Simonetti, J	1
Agarwala, P; DeLeon, J; Glass, AD; Glass, DS; Grossfeld, D; Kasselman, LJ; Reiss, AB; Renna, HA; Spiegler, P	1
Condos, R; Deshwal, H; Gibson, CD; Kugler, MC; Munger, JS	1
Kolb, MRJ; Scallan, C; Wongkarnjana, A	1
Hu, Z; Li, K; Lv, X	1
Aguilar-Ramírez, JR; Armendariz-Borunda, J; Bosques-Padilla, F; Cerda, E; Cisneros, L; Cruz, M; Flores-Murrieta, F; Gasca, F; Hernández, L; Mejía-Cuán, L; Muñoz-Espinosa, LE; Patiño, A; Poo, JL; Ramírez-Castillo, C; Tapia, G; Torre, A; Treviño, S; Velázquez, A	1
Apel, RM; Bengel, FM; Derlin, T; Freise, J; Jaeger, B; Jonigk, D; Prasse, A; Ross, TL; Seeliger, B; Shin, HO; Warnecke, G; Weiberg, D; Welte, T; Wester, HJ	1
Bi, Y; Chen, J; Chowdhury, BA; Karimi-Shah, BA; Marathe, A; Paterniti, MO; Rekić, D; Wang, Y	1
Irfan, M; Trachalaki, A; Wells, AU	1
Barber, CM; Bianchi, SM; Chaudhuri, N; Eaden, JA; Renshaw, SA	1
Chang, J; Choi, JS; Chung, KS; Jung, JY; Kang, YA; Kim, SY; Kim, YS; Lee, SH; Moon, SW; Park, MS; Song, MJ	1
Altinisik, G; Karasu, U; Ufuk, F	1
Belhassen, M; Dalon, F; Nolin, M; Van Ganse, E	1
Azuma, A; Ebina, M; Kondoh, Y; Kudoh, S; Miyazawa, S; Nukiwa, T; Ogura, T; Sakaguchi, H; Sakamoto, K; Suga, M; Sugiyama, Y; Suzuki, A; Taguchi, Y; Takahashi, H	1
Aono, Y; Enomoto, N; Fujisawa, T; Furuhashi, K; Hasegawa, H; Hozumi, H; Inui, N; Karayama, M; Kono, M; Mori, K; Nakamura, H; Nakamura, Y; Naoi, H; Suda, T; Suzuki, Y; Yokomura, K	1
Bendstrup, E; Carlson, L; Durheim, MT; Hyldgaard, C; Kalafatis, D; Myllärniemi, M; Sjåheim, T; Sköld, CM; Sutinen, EM	1
Homma, S; Isshiki, T; Kishi, K; Miyoshi, S; Nakamura, Y; Sakamoto, S; Shimizu, H; Yamasaki, A	1
Bi, Y; Chowdhury, BA; Karimi-Shah, BA; Paterniti, MO; Rekić, D; Wang, Y	1
Bonella, F; Costabel, U; Kirchgässler, KU; Kolb, M; Koschel, D; Kreuter, M; Maher, TM; Renzoni, E; Spagnolo, P; Weycker, D; Wuyts, W	1
Furuya, K; Homma, S; Isshiki, T; Kinoshita, A; Matsumoto, K; Sakamoto, S; Sekiya, M; Shimizu, H; Sugino, K	1
Leslie, K; Morell, F; Raghu, G; Vasakova, M; Walsh, S	1
Behr, J; Kreuter, M; Wälscher, J	1
Raghu, G; Richeldi, L	1
Beatson, D; Chambers, DC; Chapman, S; Corte, TJ; de Boer, S; Glaspole, I; Goh, N; Grainge, C; Holland, A; Hopkins, P; Jo, HE; Jones, L; Keir, G; Moodley, Y; Reynolds, PN; Troy, LK; Whitford, H; Wilsher, M	1
Abe, M; Ichimura, Y; Ikari, J; Matsumura, A; Matsumura, T; Suzuki, K; Tatsumi, K; Terada, J; Tsushima, K; Yamagishi, K	1
Behr, J; Günther, A; Kreuter, M; Neuser, P; Prasse, A; Rabe, K; Schade-Brittinger, C; Wagner, J	1
Grutters, JC; Kreuter, M; Quaresma, M; Richeldi, L; Ryerson, CJ; Stansen, W; Stowasser, S; Valeyre, D; Vancheri, C; Wiebe, S; Wuyts, WA	1
Boccabella, C; Comes, A; Condoluci, C; Golfi, N; Inchingolo, R; Mastrobattista, A; Richeldi, L; Smargiassi, A	1
Chiba, H; Hasegawa, Y; Ikeda, K; Kuronuma, K; Nishikiori, H; Otsuka, M; Saito, A; Shiratori, M; Takahashi, H; Yamada, G; Yokoo, K	1
Bonella, F; Kolb, M; Wollin, L	1
Caminati, A; Cassandro, R; Harari, S; Torre, O	1
Raghu, G	2
Nathan, SD	1
Arízaga Maguregui, A; González Larrocha, O; Ortega Mera, U; Romero Rojano, P	1
Bénard, S; Catella, L; Cottin, V; Le Lay, K; Luciani, L; Porte, F	1
Calvello, M; Iovene, B; Ori, M; Richeldi, L; Sgalla, G; Varone, F	1
Lewandowska, K	1
Balestro, E; Bazzan, E; Biondini, D; Cerri, S; Clini, E; Cocconcelli, E; Cosio, MG; Foschino Barbaro, MP; Gregori, D; Lacedonia, D; Luppi, F; Milaneschi, R; Saetta, M; Spagnolo, P	1
Aryal, S; Nathan, SD	1
Ask, K; Bellaye, PS; Gauldie, J; Granton, E; Hambly, N; Iglarz, M; Imani, J; Kolb, M; Sato, S; Shimbori, C; Upagupta, C; Yanagihara, T	1
Azuma, A; Bando, M; Date, H; Ebina, M; Fukuoka, J; Gemma, A; Goto, Y; Hasegawa, Y; Hattori, N; Homma, S; Inase, N; Inoue, Y; Ishii, Y; Izumi, S; Johkoh, T; Kido, T; Kishaba, T; Kishi, K; Miyamoto, A; Mukae, H; Nakayama, T; Nishioka, Y; Ogura, T; Sakamoto, S; Sasaki, S; Suda, T; Sugino, K; Taguchi, Y; Takahashi, H; Takahashi, K; Taniguchi, H; Watanabe, K; Yokoyama, A; Yoshino, I	1
Arron, JR; Cabanski, CR; Collard, HR; Gu, C; Jia, G; Ley, B; Neighbors, M; Peng, K; Ramalingam, TR; Ray, JM; Sheng, XR; Tew, GW; Wolters, PJ	1
Antoniou, KM; Bibaki, E; Detorakis, S; Margaritopoulos, GA; Papastratigakis, G; Trachalaki, A; Tzanakis, N; Vasarmidi, E; Wells, AU	1
Costabel, U; Glaspole, I; Glassberg, MK; Lancaster, LH; Lederer, DJ; Limb, SL; Morgenthien, EA; Nathan, SD; Pereira, CA; Trzaskoma, B; Wells, AU	1
Bergna, M; de Andrade, J; Falk, J; Hallowell, R; Jouneau, S; Kondoh, Y; Morrow, L; Randerath, W; Richeldi, L; Strek, M; Tabaj, G; Varone, F	1
Bartos, V; Binkova, I; Bittenglova, R; Doubkova, M; Homolka, J; Janotova, M; Kervitzer, J; Kolek, V; Kralova, R; Kriegova, E; Lacina, L; Lisa, P; Lnenicka, J; Lostakova, V; Ondrejka, G; Petrik, F; Plackova, M; Psikalova, J; Rihak, V; Snizek, T; Sterclova, M; Strenkova, J; Suldova, H; Svoboda, M; Tyl, R; Vasakova, M; Zurkova, M	1
Blackwell, TS; Kropski, JA	1
Bennett, D; Fossi, A; Fui, A; Mazzei, MA; Pieroni, M; Refini, RM; Rottoli, P; Valentini, ML	1
Cottin, V; Fischer, A; Harari, S; Quaresma, M; Stowasser, S; Wollin, L	1
Kishaba, T	1
Albera, C; Costabel, U; Gilberg, F; Glassberg, MK; Kirchgaessler, KU; Lancaster, LH; Noble, PW; Petzinger, U; Wuyts, WA	1
Baldi, F; Macagno, F; Panico, L; Pasciuto, G; Richeldi, L	1
Dobashi, K; Hachisu, Y; Hisada, T; Izuhara, K; Kaira, K; Koga, Y; Ohta, S; Ono, J; Tsurumaki, H; Yatomi, M	1
Ihle, F; Neurohr, C; von Wulffen, W	1
Ancochea, J; Bollo, E; Fernández-Fabrellas, E; Franquet, T; Molina-Molina, M; Montero, MA; Serrano-Mollar, A; Xaubet, A	1
Homma, S; Ishida, F; Isobe, K; Itoh, T; Muramatsu, Y; Sakamoto, S; Satoh, K; Sugino, K	1
Clark, P; Landells, LJ; Naidoo, B; Robertson, J	1
Tampe, D; Zeisberg, M	1
Babovic-Vuksanovic, D; Balis, FM; Blaney, SM; Cohen, B; Dombi, E; Fox, E; Goldman, S; Goodspeed, W; Goodwin, A; Kieran, MW; King, A; Martin, S; Packer, RJ; Patronas, N; Solomon, J; Steinberg, SM; Widemann, BC; Wolters, PL	1
Bradford, WZ; Castro-Bernardini, S; Fagan, EA; Glaspole, I; Glassberg, MK; Gorina, E; Hopkins, PM; Kardatzke, D; King, TE; Lancaster, L; Lederer, DJ; Nathan, SD; Noble, PW; Pereira, CA; Sahn, SA; Sussman, R; Swigris, JJ	1
Hoffstein, V; Kardos, P; Kreuter, M	1
Ehlers-Tenenbaum, S; Herth, FJ; Heussel, CP; Kahn, N; Kreuter, M; Oltmanns, U; Palmowski, K; Puderbach, M; Schnabel, PA; Träger, A; Warth, A; Wenz, H; Wiebel, M	1
Cottin, V	1
Albera, C; Bradford, WZ; Costabel, U; du Bois, RM; Hormel, P; King, TE; Noble, PW; Sahn, SA; Valeyre, D	1
Iwata, T; Mizobuchi, T; Nagato, K; Nakajima, T; Nakatani, Y; Ota, S; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I	1
Kunii, E; Moriyama, S; Niimi, A; Ohkubo, H	1
Collard, HR; Spagnolo, P; Wells, AU	1
Kaminski, N; Rosas, IO	1
Corte, T; King, TE; Moodley, Y; Richeldi, L	1
Einecke, D	1
Diso, D; Frati, G; Ialleni, E; Ialongo, P; Paone, G; Peruzzi, M; Quagliarini, F; Rose, D; Sebastiani, A; Venuta, F	1
Agostini, C; Albera, C; Bandelli, GP; Bargagli, E; Biffi, A; Bocchino, M; Caminati, A; Cerri, S; Cinetto, F; Confalonieri, M; Della Porta, R; Farinelli, G; Giunta, V; Harari, S; Luppi, F; Mari, A; Pesci, A; Poletti, V; Puglisi, S; Saltini, C; Sanduzzi, A; Sebastiani, A; Specchia, C; Tirelli, F; Tomassetti, S; Vancheri, C	1
Funke, M; Geiser, T	1
Bauer, C; Buzan, T; Colombi, D; Dinkel, J; Herth, F; Heussel, CP; Kauczor, HU; Kreuter, M; Nabers, D; Obermayer, B; Oltmanns, U; Palmowski, K; Sverzellati, N; Weinheimer, O	1
Antoniou, K; Costabel, U; Crestani, B; Egan, J; Margaritopoulos, G; Poletti, V; Wells, AU	1
Azuma, A; Bando, M; Chida, K; Inoue, Y; Kakutani, S; Kudoh, S; Niimi, Y; Nukiwa, T; Ogura, T; Suga, M; Sugiyama, Y; Taniguchi, H	1
Kremer, MR; Wand, O	1
Elmufdi, F; Henke, CA; Kim, HJ; Perlman, DM; Tomic, R	1
Azuma, A; Ebina, M; Kondoh, Y; Kudoh, S; Nakata, K; Nukiwa, T; Ogura, T; Suga, M; Sugiyama, Y; Taguchi, Y; Takahashi, H; Taniguchi, H	1
Bianchini, E; Bocchino, M; Carbonelli, CM; Cerri, S; Cossarizza, A; De Biasi, S; Gibellini, L; Luppi, F; Montanari, G; Persiani, E; Richeldi, L; Sgalla, G; Vancheri, C; Zamparelli, AS; Zucchi, L	1
Noble, PW; Selvaggio, AS	1
Arita, M; Fukuda, Y; Hashimoto, T; Ishida, T; Ito, A; Ito, I; Iwasaku, M; Konishi, S; Kourogi, Y; Kunimasa, K; Masuda, G; Nishiyama, A; Tachibana, H; Takaiwa, T; Tanaka, M; Tokioka, F; Tsubouchi, K; Watanabe, N; Yoshioka, H	1
Albera, C; Bradford, WZ; Costabel, U; du Bois, RM; Fagan, EA; Fishman, RS; Glaspole, I; Glassberg, MK; King, TE; Lancaster, L; Lederer, DJ; Leff, JA; Nathan, SD; Noble, PW; Pereira, CA; Swigris, JJ; Valeyre, D	1
Bonella, F; Kreuter, M; Maher, TM; Spagnolo, P; Wijsenbeek, M	1
Azuma, A; Bando, M; Homma, S; Ogura, T; Sugiyama, Y; Taniguchi, H; Watanabe, K; Yamauchi, H	1
Bradford, WZ; Collard, HR; du Bois, RM; Ley, B; Vittinghoff, E; Weycker, D	1
Baba, T; Ikeda, S; Kitamura, H; Morita, M; Ogura, T; Sekine, A; Yamakawa, H	1
Albera, C; Bradford, WZ; Costabel, U; du Bois, RM; Fagan, EA; Fishman, RS; Glaspole, I; Glassberg, MK; Glasscock, KF; King, TE; Lancaster, L; Lederer, DJ; Lin, Z; Nathan, SD; Noble, PW; Pereira, CA; Swigris, JJ; Valeyre, D; Wells, AU	1
Hanada, S; Kishi, K; Kurosaki, A; Miyamoto, A; Mochizuki, S; Morokawa, N; Murase, K; Ogawa, K; Takahashi, Y; Takaya, H; Takeyasu, M; Uruga, H	1
Costabel, U; Herth, FJ; Kirchgaessler, KU; Kolb, M; Koschel, D; Kreuter, M; Maher, TM; Renzoni, E; Spagnolo, P; Weycker, D; Wuyts, W	1
Beltramo, G; Borie, R; Crestani, B; Justet, A; Manali, ED; Pradère, P; Spagnolo, P	1
Corte, TJ; Jo, HE; Moodley, Y; Randhawa, S	1
Asato, Y; Azuma, A; Chida, M; Fukuoka, J; Hiroshima, K; Ikeda, N; Iwasawa, T; Iwata, T; Katakami, N; Kuwano, K; Matsuura, M; Mitsudomi, T; Nakagawa, K; Nakanishi, Y; Okada, M; Okami, J; Okubo, K; Sakai, S; Sakamoto, K; Tada, H; Takenoyama, M; Tomii, K; Tsuboi, M; Yamashita, M; Yamashita, Y; Yokouchi, H; Yoshida, S; Yoshimura, K; Yoshino, I	1
Albera, C; Costabel, U; Fagan, EA; Glassberg, MK; Gorina, E; Lancaster, L; Lederer, DJ; Nathan, SD; Spirig, D; Swigris, JJ	1
Adegunsoye, A; Strek, ME	1
Roman, J; Santiago-Cornier, A; Vergne, Y; Vicary, GW; Young, LR	1
Fujiwara, T; Iwata, T; Nakajima, T; Suzuki, H; Wada, H; Yoshida, S; Yoshino, I	1
Robinson, HC	1
Clarke, DL; Crestani, B; Murray, LA; Sleeman, MA	1
Chen, S; Chen, Z; Gu, L; Guo, L; Li, T; Sun, F; Tan, X; Wang, X; Ye, S	1
Bonella, F; Costabel, U; Kirchgaessler, KU; Kolb, M; Kreuter, M; Maher, TM; Spagnolo, P; Weycker, D	1
Delanote, I; Verbeken, EK; Verleden, GM; Vos, R; Wuyts, WA; Yserbyt, J	1
Jeldres, A; Labarca, G	1
Antony, VB; Bae, S; de Andrade, J; Li, FJ; Li, H; Liu, G; Liu, RM; Luckhardt, T; Rangarajan, S; Surolia, R; Thannickal, VJ; Wang, Z; Zhou, Y	1
Araki, K; Hirai, K; Hoshino, K; Igarashi, T; Ishii, N; Kubo, N; Kuwano, H; Saitoh, F; Shirabe, K; Tsukagoshi, M; Watanabe, A; Yamanaka, T	1
Aiello, M; Bertorelli, G; Bocchino, M; Chetta, A; Fiore-Donati, A; Fois, A; Marinari, S; Oggionni, T; Polla, B; Rosi, E; Sanduzzi, A; Stanziola, A; Varone, F	1
George, PM; Wells, AU	1
Acosta, O; Ancochea, J; Bollo, E; Castillo, D; Fernández-Fabrellas, E; Molina-Molina, M; Rodríguez-Portal, JA; Valenzuela, C; Xaubet, A	1
Chikanishi, T; Fujimori, A; Itoh, H; Iwatsuki, Y; Nakajima, H; Okada, M; Takakuta, K; Tanokura, A; Yamamoto, M	1
Cho, ME; Kopp, JB	1
Declèves, AE; Sharma, K	1
Azuma, A	1
Cho, M; Donohue, M; Dunn, SR; Falkner, B; Fervenza, FC; Francos, B; Ix, JH; Kopp, JB; Mathew, AV; McGowan, TA; Pflueger, A; Ramachandrarao, S; Sharma, K; Sharma, S; Xu, R	1
Beaulieu, MC; Levin, A	1
Azuma, A; Ebina, M; Kondoh, Y; Kudoh, S; Nakata, K; Nukiwa, T; Ogura, T; Sato, A; Suga, M; Sugiyama, Y; Taguchi, Y; Takahashi, H; Taniguchi, H	1
Abramowitz, MK; Bauer, C; Hostetter, TH; Melamed, ML; Turner, JM	1
Günther, A; Korfei, M; Mahavadi, P; Markart, P; Ruppert, C; von der Beck, D	1
Dosanjh, A	1
Call, TG; Elliott, MA; Gray, LA; Hoagland, HC; Hook, CC; Li, CY; Margolin, S; Mesa, RA; Schroeder, GS; Tefferi, A; Yoon, SY	1

Reviews

51 review(s) available for pirfenidone and Disease Exacerbation

Article	Year
Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape. The American journal of managed care, 2019, Volume: 25, Issue:11 Suppl Topics: Age Distribution; Aging; Antineoplastic Agents; Chronic Disease; Comorbidity; Disease Progression; Health Expenditures; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Patient Education as Topic; Practice Guidelines as Topic; Pyridones; Sex Distribution	2019
Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clinical rheumatology, 2019, Volume: 38, Issue:10 Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppression Therapy; Indoles; Kaplan-Meier Estimate; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Risk Factors; Tomography, X-Ray Computed	2019
The therapy of idiopathic pulmonary fibrosis: what is next? European respiratory review : an official journal of the European Respiratory Society, 2019, Sep-30, Volume: 28, Issue:153 Topics: Animals; Comorbidity; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Transplantation; Molecular Targeted Therapy; Palliative Care; Pyridones; Respiratory System Agents; Respiratory Therapy; Risk Factors; Treatment Outcome	2019
Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update. Expert review of respiratory medicine, 2019, Volume: 13, Issue:12 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Protein Kinase Inhibitors; Pyridones; Treatment Outcome	2019
Lung transplantation for idiopathic pulmonary fibrosis. Presse medicale (Paris, France : 1983), 2020, Volume: 49, Issue:2 Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Comorbidity; Disease Progression; Frailty; Gastroesophageal Reflux; Humans; Hypertension, Pulmonary; Idiopathic Interstitial Pneumonias; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Lung Transplantation; Prognosis; Pyridones; Telomere Shortening	2020
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert opinion on investigational drugs, 2020, Volume: 29, Issue:8 Topics: Animals; Antibodies, Monoclonal, Humanized; Connective Tissue Growth Factor; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2020
Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches. Respiratory investigation, 2020, Volume: 58, Issue:5 Topics: Aged; Aged, 80 and over; Biomarkers; Disease Progression; Female; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Male; Middle Aged; Prognosis; Pyridones; Telomere	2020
Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease. Lung, 2020, Volume: 198, Issue:4 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Vital Capacity	2020
Autophagy and Pulmonary Fibrosis. Advances in experimental medicine and biology, 2020, Volume: 1207 Topics: Autophagy; Disease Progression; Humans; Indoles; Pulmonary Fibrosis; Pyridones	2020
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:2 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic	2021
Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?). Current opinion in pulmonary medicine, 2017, Volume: 23, Issue:5 Topics: Disease Progression; Enzyme Inhibitors; Humans; Indoles; Lung Diseases, Interstitial; Observational Studies as Topic; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Current approaches to the management of idiopathic pulmonary fibrosis. Respiratory medicine, 2017, Volume: 129 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Middle Aged; Palliative Care; Patient Education as Topic; Practice Guidelines as Topic; Prevalence; Pyridones; Quality of Life; Young Adult	2017
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:15 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Approval; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Therapeutic targets in idiopathic pulmonary fibrosis. Respiratory medicine, 2017, Volume: 131 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Molecular Targeted Therapy; Pyridones; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2017
Severe idiopathic pulmonary fibrosis: what can be done? European respiratory review : an official journal of the European Respiratory Society, 2017, Sep-30, Volume: 26, Issue:145 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Transplantation; Palliative Care; Pyridones; Respiratory Function Tests; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome	2017
Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. European respiratory review : an official journal of the European Respiratory Society, 2017, Sep-30, Volume: 26, Issue:145 Topics: Animals; Diffusion of Innovation; Disease Progression; Drug Discovery; Drugs, Investigational; Forecasting; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Remission Induction; Respiratory System Agents; Severity of Illness Index; Treatment Outcome	2017
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. The European respiratory journal, 2017, Volume: 50, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome	2017
Idiopathic pulmonary fibrosis: pathogenesis and management. Respiratory research, 2018, 02-22, Volume: 19, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Management; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Tomography, X-Ray Computed	2018
[Nintedanib in the treatment of fibrosing interstital lung diseases]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2018, Mar-27, Volume: 44, Issue:261 Topics: Disease Progression; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridones; Treatment Outcome	2018
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis. Expert opinion on emerging drugs, 2018, Volume: 23, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Design; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2018
Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respiratory investigation, 2018, Volume: 56, Issue:4 Topics: Acetylcysteine; Administration, Inhalation; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Disease Progression; Drug Therapy, Combination; Evidence-Based Medicine; Glycine; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Japan; Lung Neoplasms; Meta-Analysis as Topic; Practice Guidelines as Topic; Prognosis; Pyridones; Quality of Health Care; Sulfonamides; Survival Rate	2018
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. European respiratory review : an official journal of the European Respiratory Society, 2018, Dec-31, Volume: 27, Issue:150 Topics: Disease Progression; Humans; Indoles; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Risk Factors; Treatment Outcome	2018
Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis. Annual review of medicine, 2019, 01-27, Volume: 70 Topics: Aged; Biopsy, Needle; Chronic Disease; Comprehension; Disease Management; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunohistochemistry; Indoles; Lung Transplantation; Male; Middle Aged; Precision Medicine; Prognosis; Pyridones; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Treatment Outcome	2019
Fibrosing interstitial lung diseases: knowns and unknowns. European respiratory review : an official journal of the European Respiratory Society, 2019, Mar-31, Volume: 28, Issue:151 Topics: Disease Progression; Health Status; Humans; Indoles; Lung; Lung Diseases, Interstitial; Phenotype; Pulmonary Fibrosis; Pyridones; Quality of Life; Respiratory System Agents; Risk Factors; Severity of Illness Index; Treatment Outcome	2019
Evaluation and management of Idiopathic Pulmonary Fibrosis. Respiratory investigation, 2019, Volume: 57, Issue:4 Topics: Biomarkers; Chronic Disease; Cough; Diagnosis, Differential; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Indoles; L-Lactate Dehydrogenase; Mucin-1; Pyridones; Respiratory Function Tests; Tomography, X-Ray Computed; Vital Capacity	2019
Current and Future Idiopathic Pulmonary Fibrosis Therapy. The American journal of the medical sciences, 2019, Volume: 357, Issue:5 Topics: Anti-Inflammatory Agents; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2019
Potential approaches to reverse or repair renal fibrosis. Nature reviews. Nephrology, 2014, Volume: 10, Issue:4 Topics: Anti-Inflammatory Agents; Bone Morphogenetic Protein 7; Connective Tissue Growth Factor; Disease Progression; Endothelin-1; Epigenesis, Genetic; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Microcirculation; Phosphodiesterase Inhibitors; Pyridones; Transforming Growth Factor beta	2014
[Idiopathic pulmonary fibrosis]. La Revue du praticien, 2014, Volume: 64, Issue:7 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones	2014
Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug discovery today, 2015, Volume: 20, Issue:5 Topics: Animals; Comorbidity; Disease Models, Animal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Risk Factors; Time Factors; Treatment Outcome	2015
Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Respirology (Carlton, Vic.), 2015, Volume: 20, Issue:3 Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease Management; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Treatment Outcome; Tumor Necrosis Factor-alpha	2015
Idiopathic pulmonary fibrosis: the turning point is now! Swiss medical weekly, 2015, Volume: 145 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Disease Progression; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones	2015
Challenges in IPF diagnosis, current management and future perspectives. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2015, Aug-03, Volume: 32 Suppl 1 Topics: Aged; Biopsy, Needle; Disease Management; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunohistochemistry; Male; Middle Aged; Needs Assessment; Practice Guidelines as Topic; Prognosis; Pyridones; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Survival Analysis; Tomography, X-Ray Computed	2015
[Novel therapies for idiopathic pulmonary fibrosis]. Harefuah, 2015, Volume: 154, Issue:7 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Respiratory Mucosa; Survival Rate	2015
Novel mechanisms and treatment of idiopathic pulmonary fibrosis. Discovery medicine, 2015, Volume: 20, Issue:109 Topics: Clinical Trials as Topic; Disease Progression; Environmental Exposure; Fibroblasts; Gastroesophageal Reflux; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mutation; Myofibroblasts; Polymorphism, Genetic; Prognosis; Pyridones; Treatment Outcome	2015
Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis. Annual review of medicine, 2016, Volume: 67 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Disease-Free Survival; Humans; Idiopathic Pulmonary Fibrosis; Pyridones	2016
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. The European respiratory journal, 2016, Volume: 47, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Disease Progression; Exercise Test; Female; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; International Cooperation; Male; Middle Aged; Pulmonary Diffusing Capacity; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity	2016
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. BioMed research international, 2015, Volume: 2015 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Disease Management; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones	2015
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:5 Topics: Aged; Antacids; Clinical Trials, Phase III as Topic; Disease Progression; Exercise Tolerance; Female; Gastroesophageal Reflux; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Lung; Male; Middle Aged; Patient Admission; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity; Walk Test	2016
Pharmacological management of IPF. Respirology (Carlton, Vic.), 2016, Volume: 21, Issue:4 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Immunomodulation; Immunosuppressive Agents; Indoles; Male; Middle Aged; Practice Guidelines as Topic; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome	2016
Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest, 2016, Volume: 150, Issue:6 Topics: Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Connective Tissue Diseases; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Prognosis; Pyridones	2016
Pulmonary Fibrosis in Hermansky-Pudlak Syndrome. Annals of the American Thoracic Society, 2016, Volume: 13, Issue:10 Topics: Animals; Biomarkers; Disease Progression; Hermanski-Pudlak Syndrome; Hispanic or Latino; Humans; Indoles; Lung Transplantation; Membrane Proteins; Mice; Mutation; Puerto Rico; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed	2016
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis? Pharmacology & therapeutics, 2017, Volume: 169 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Precision Medicine; Prognosis; Pyridones	2017
Is pirfenidone effective for idiopathic pulmonary fibrosis? Medwave, 2017, Jan-17, Volume: 17, Issue:Suppl1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic	2017
Perioperative management of hepatectomy in patients with interstitial pneumonia: a report of three cases and a literature review. Surgery today, 2017, Volume: 47, Issue:10 Topics: Aged; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Hepatectomy; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Male; Mucin-1; Perioperative Care; Postoperative Complications; Pyridones; Respiration Disorders; Tomography, X-Ray Computed	2017
The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulmonary pharmacology & therapeutics, 2017, Volume: 44 Topics: Disease Progression; Early Diagnosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Italy; Patient Care Team; Patient-Centered Care; Prognosis; Protein Kinase Inhibitors; Pyridones	2017
Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert review of clinical pharmacology, 2017, Volume: 10, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Endpoint Determination; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Drug Evaluation; Fibrosis; Humans; Kidney; Kidney Diseases; Pyridones	2010
New pharmacological treatments for improving renal outcomes in diabetes. Nature reviews. Nephrology, 2010, Volume: 6, Issue:6 Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biomarkers; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Protein Kinase C; Pyridones; Renin; Transforming Growth Factor beta	2010
Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert review of respiratory medicine, 2010, Volume: 4, Issue:3 Topics: Animals; Clinical Trials as Topic; Disease Progression; Drug Approval; Humans; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Recovery of Function; Respiratory System Agents; Severity of Illness Index; Time Factors; Treatment Outcome	2010
Treatment of chronic kidney disease. Kidney international, 2012, Volume: 81, Issue:4 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Diabetes Mellitus, Type 2; Disease Progression; Endothelin-1; Humans; Hypertension; Kidney Failure, Chronic; Oleanolic Acid; Pyridones; Renal Insufficiency, Chronic; Renin-Angiotensin System	2012
Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society, 2012, Jun-01, Volume: 21, Issue:124 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Enzyme Inhibitors; Epithelial Cells; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pulmonary Alveoli; Pyridones	2012

Trials

22 trial(s) available for pirfenidone and Disease Exacerbation

Article	Year
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis. Scientific reports, 2021, 09-08, Volume: 11, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Propensity Score; Pyridones; Sildenafil Citrate; Treatment Outcome; Vital Capacity	2021
Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration. Medicine, 2022, Jun-03, Volume: 101, Issue:22 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome; Vital Capacity	2022
Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax, 2023, Volume: 78, Issue:11 Topics: Adult; Alveolitis, Extrinsic Allergic; COVID-19; Disease Progression; Double-Blind Method; Humans; Idiopathic Pulmonary Fibrosis; Pandemics; Pyridones; Treatment Outcome; Vital Capacity	2023
Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy. Respiratory medicine, 2023, Volume: 217 Topics: COVID-19; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Phenotype; Pneumonia; Pyridones	2023
Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. Respiratory research, 2019, Oct-24, Volume: 20, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Belgium; Disease Progression; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Luxembourg; Male; Middle Aged; Mortality; Pyridones; Registries; Respiratory Function Tests; Treatment Outcome	2019
Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study. Hepatology international, 2020, Volume: 14, Issue:5 Topics: Anti-Inflammatory Agents; Delayed-Action Preparations; Disease Progression; Elasticity Imaging Techniques; Female; Humans; Liver; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Proof of Concept Study; Pyridones; Quality of Life; Standard of Care; Treatment Outcome	2020
The Effect of Pirfenidone on the Prescription of Antibiotics and Antitussive Drugs in Patients With Idiopathic Pulmonary Fibrosis: A Post Hoc Exploratory Analysis of Phase III Clinical Trial. Chest, 2021, Volume: 160, Issue:4 Topics: Aged; Anti-Bacterial Agents; Antifibrotic Agents; Antitussive Agents; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Polypharmacy; Pyridones; Treatment Outcome	2021
Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC pulmonary medicine, 2017, Sep-06, Volume: 17, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Connective Tissue Diseases; Disease Progression; Double-Blind Method; Female; Humans; Lung; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Research Design; Treatment Outcome; Vital Capacity; Young Adult	2017
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American journal of respiratory and critical care medicine, 2018, 02-01, Volume: 197, Issue:3 Topics: Aged; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Patient Safety; Pyridones; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome	2018
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, Volume: 155, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Disease Progression; Dose-Response Relationship, Drug; Europe; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Survival Rate; Treatment Outcome; United States; Vital Capacity	2019
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respiratory research, 2019, Mar-12, Volume: 20, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Treatment Outcome	2019
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatric blood & cancer, 2014, Volume: 61, Issue:9 Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Disease Progression; Female; Follow-Up Studies; Humans; Male; Neoplasm Staging; Neurofibroma, Plexiform; Neurofibromatosis 1; Prognosis; Pyridones; Quality of Life; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; Young Adult	2014
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England journal of medicine, 2014, May-29, Volume: 370, Issue:22 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Treatment Outcome; Vital Capacity	2014
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014, Oct-20, Volume: 31, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Australia; Disease Progression; Europe; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; North America; Prospective Studies; Pulmonary Diffusing Capacity; Pyridones; Time Factors; Treatment Outcome; Vital Capacity	2014
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine, 2016, 09-15, Volume: 194, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dyspnea; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Models, Statistical; Proportional Hazards Models; Pyridones; Risk Assessment; Risk Factors; Surveys and Questionnaires; Vital Capacity	2016
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax, 2016, Volume: 71, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Pyridones; Research Design; Treatment Outcome; Vital Capacity	2016
A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). Respiratory research, 2016, 07-22, Volume: 17, Issue:1 Topics: Administration, Oral; Disease Progression; Drug Administration Schedule; Humans; Idiopathic Pulmonary Fibrosis; Japan; Lung Neoplasms; Pneumonectomy; Pyridones; Risk Factors; Time Factors; Treatment Outcome	2016
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. The European respiratory journal, 2016, Volume: 48, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dyspnea; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Respiratory Function Tests; Surveys and Questionnaires; Tidal Volume; Treatment Outcome; Vital Capacity	2016
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax, 2017, Volume: 72, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind Method; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Risk Factors; Treatment Outcome	2017
Pirfenidone for diabetic nephropathy. Journal of the American Society of Nephrology : JASN, 2011, Volume: 22, Issue:6 Topics: Adult; Aged; Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Creatinine; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrosis; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Pyridones; Treatment Outcome	2011
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respiratory research, 2011, Jul-15, Volume: 12 Topics: Aged; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Idiopathic Pulmonary Fibrosis; Japan; Kaplan-Meier Estimate; Lung; Middle Aged; Pyridones; Respiratory System Agents; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vital Capacity	2011
A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. British journal of haematology, 2001, Volume: 114, Issue:1 Topics: Administration, Oral; Adult; Aged; Antifibrinolytic Agents; Bone Marrow; Disease Progression; Female; Humans; Male; Middle Aged; Primary Myelofibrosis; Prospective Studies; Pyridones; Treatment Failure	2001

Other Studies

68 other study(ies) available for pirfenidone and Disease Exacerbation

Article	Year
Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study. European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:20 Topics: Aged; Aged, 80 and over; Antifibrotic Agents; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Prospective Studies; Pyridones; Respiratory Function Tests; Treatment Outcome; Vital Capacity	2021
Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Cells, 2022, 01-02, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Prognosis; Pyridones; Treatment Outcome	2022
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust. BMC pulmonary medicine, 2019, Sep-05, Volume: 19, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dust; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Italy; Male; Middle Aged; Multivariate Analysis; Occupational Exposure; Prognosis; Prospective Studies; Pyridones; Regression Analysis; Respiratory Function Tests; Treatment Outcome	2019
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. BMC pulmonary medicine, 2019, Nov-12, Volume: 19, Issue:1 Topics: Aged; Disease Progression; Female; Humans; Indoles; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Phenotype; Pulmonary Fibrosis; Pyridones; Retrospective Studies; Risk Factors; Tertiary Care Centers; Tomography, X-Ray Computed	2019
Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis. Surgery today, 2020, Volume: 50, Issue:5 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Perioperative Care; Postoperative Period; Pyridones; Retrospective Studies; Treatment Outcome	2020
Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC pulmonary medicine, 2020, Jan-31, Volume: 20, Issue:1 Topics: Aged; Biomarkers; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Logistic Models; Male; Middle Aged; Mucin-1; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2020
Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. Respiratory investigation, 2020, Volume: 58, Issue:3 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Predictive Value of Tests; Pyridones; Radiographic Image Enhancement; Retrospective Studies; Tomography, X-Ray Computed; Vital Capacity	2020
Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis. Surgery today, 2020, Volume: 50, Issue:8 Topics: Aged; Aged, 80 and over; Disease Progression; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Negative Results; Patient Selection; Perioperative Care; Postoperative Complications; Prognosis; Pyridones; Survival Rate	2020
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. Respirology (Carlton, Vic.), 2020, Volume: 25, Issue:11 Topics: Antineoplastic Agents; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Italy; Longitudinal Studies; Male; Middle Aged; Mortality; Practice Patterns, Physicians'; Pyridones; Treatment Outcome	2020
A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study. BMC pulmonary medicine, 2020, May-04, Volume: 20, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Male; Medication Adherence; Middle Aged; Poland; Pyridones; Respiratory Function Tests; Retrospective Studies; Treatment Outcome; Walk Test	2020
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. Current opinion in pulmonary medicine, 2020, Volume: 26, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Humans; Indoles; Lung Diseases, Interstitial; Phenotype; Prognosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyridones; Treatment Outcome; Vital Capacity	2020
Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. Chest, 2021, Volume: 159, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Pharmacological; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunohistochemistry; Lung; Male; Patient Acuity; Positron Emission Tomography Computed Tomography; Prognosis; Pyridones; Receptors, CXCR4; Up-Regulation	2021
A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients. Journal of pharmacokinetics and pharmacodynamics, 2021, Volume: 48, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Longitudinal Studies; Lung; Male; Middle Aged; Models, Biological; Prognosis; Pyridones; Respiratory Function Tests; Risk Factors; Smoking; Time Factors; Treatment Outcome; Vital Capacity	2021
Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2020, Volume: 37, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; England; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Pyridones; Recovery of Function; Retrospective Studies; Time Factors; Treatment Outcome; Vital Capacity	2020
Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital. Scientific reports, 2020, 12-04, Volume: 10, Issue:1 Topics: Aged; Anorexia; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dyspepsia; Female; Hospitals, University; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Nausea; Pyridones; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Vital Capacity	2020
Pleuroparenchymal fibroelastosis in a patient with systemic sclerosis. Rheumatology (Oxford, England), 2021, 08-02, Volume: 60, Issue:8 Topics: Aged; Bronchiectasis; Disease Progression; Elastic Tissue; Female; Humans; Lung Diseases, Interstitial; Pleural Diseases; Pulmonary Diffusing Capacity; Pulmonary Fibrosis; Pyridones; Scleroderma, Systemic; Tomography, X-Ray Computed; Vital Capacity	2021
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respiratory research, 2021, May-04, Volume: 22, Issue:1 Topics: Aged; Aged, 80 and over; Databases, Factual; Disease Progression; Female; France; Health Status; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Middle Aged; Pyridones; Respiratory System Agents; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2021
Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study. BMC pulmonary medicine, 2021, Jul-12, Volume: 21, Issue:1 Topics: Aged; Disease Progression; Drug Administration Schedule; Drug Substitution; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Japan; Male; Prognosis; Propensity Score; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2021
Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort. Respirology (Carlton, Vic.), 2021, Volume: 26, Issue:10 Topics: Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome; Vital Capacity	2021
Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience. Respiratory medicine, 2021, Volume: 187 Topics: Aged; Aged, 80 and over; Antifibrotic Agents; Disease Progression; Female; Humans; Incidence; Indoles; Male; Pulmonary Fibrosis; Pyridones; Time Factors; Treatment Outcome	2021
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2017, Volume: 14, Issue:9 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Multivariate Analysis; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vital Capacity	2017
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration; international review of thoracic diseases, 2017, Volume: 93, Issue:6 Topics: Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Disease Progression; Exercise Tolerance; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Mortality; Proton Pump Inhibitors; Pyridones; Respiratory Function Tests; Survival Rate; Vital Capacity; Walk Test	2017
Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study. Respiratory medicine, 2017, Volume: 126 Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Recombinant Proteins; Retrospective Studies; Risk Factors; Survival Analysis; Thrombomodulin; Treatment Outcome; Vital Capacity	2017
Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. American journal of respiratory and critical care medicine, 2017, Sep-15, Volume: 196, Issue:6 Topics: Acute Disease; Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Bronchoalveolar Lavage Fluid; Chronic Disease; Disease Progression; Enzyme Inhibitors; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Indoles; Lung; Lung Transplantation; Pyridones; Tomography, X-Ray Computed	2017
Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology (Carlton, Vic.), 2017, Volume: 22, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Australia; Comorbidity; Disease Progression; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Indoles; New Zealand; Pulmonary Medicine; Pyridones; Randomized Controlled Trials as Topic; Societies, Medical	2017
The effects of pirfenidone in patients with an acute exacerbation of interstitial pneumonia. The clinical respiratory journal, 2018, Volume: 12, Issue:4 Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Japan; Male; Prognosis; Pyridones; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Necrosis Factor-alpha	2018
Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respiratory medicine, 2017, Volume: 131 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Disease-Free Survival; Female; Humans; Idiopathic Pulmonary Fibrosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Pulmonary Surfactant-Associated Protein D; Pyridones; Retrospective Studies; Survival Rate; Treatment Outcome; Vital Capacity	2017
Evaluating new treatment options. The American journal of managed care, 2017, Volume: 23, Issue:11 Suppl Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Enzyme Inhibitors; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Lung; Male; Middle Aged; Pyridones; United States	2017
Recommendations for perioperative management of new pharmacological antifibrotic therapy in idiopathic pulmonary fibrosis. Revista espanola de anestesiologia y reanimacion, 2018, Volume: 65, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Progression; Enzyme Inhibitors; Fibroblasts; Hemodynamics; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Intraoperative Complications; Multicenter Studies as Topic; Perioperative Care; Postoperative Complications; Preanesthetic Medication; Pyridones; Vital Capacity	2018
Health economic evaluation in idiopathic pulmonary fibrosis in France. Current medical research and opinion, 2018, Volume: 34, Issue:10 Topics: Cost-Benefit Analysis; Disease Progression; Female; France; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Pyridones; Quality of Life; Quality-Adjusted Life Years; Respiratory System Agents; Treatment Outcome	2018
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. Scientific reports, 2018, 04-13, Volume: 8, Issue:1 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyridones; Treatment Outcome; Vital Capacity	2018
Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension. The European respiratory journal, 2018, Volume: 52, Issue:2 Topics: Animals; Cell Differentiation; Disease Progression; Female; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Lung; Male; Myofibroblasts; Pulmonary Fibrosis; Pyridones; Pyrimidines; Rats; Rats, Sprague-Dawley; Sulfonamides; Transforming Growth Factor beta1	2018
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. The Lancet. Respiratory medicine, 2018, Volume: 6, Issue:8 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Clinical Trials as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Male; Proportional Hazards Models; Pyridones	2018
Pirfenidone improves survival in IPF: results from a real-life study. BMC pulmonary medicine, 2018, Nov-23, Volume: 18, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Greece; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Vital Capacity	2018
Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respiratory research, 2019, Jan-21, Volume: 20, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Czech Republic; Disease Progression; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Registries; Respiratory Function Tests; Survival Rate; Treatment Outcome; Vital Capacity	2019
Pirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study. Lung, 2019, Volume: 197, Issue:2 Topics: Aged; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Pyridones; Retrospective Studies; Time Factors; Treatment Outcome	2019
Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels. Medicina (Kaunas, Lithuania), 2019, May-17, Volume: 55, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion Molecules; Cough; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Male; Mucin-1; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Pyridones	2019
Pirfenidone: a potential therapy for progressive lung allograft dysfunction? The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2013, Volume: 32, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Cell Proliferation; Disease Progression; Female; Fibrosis; Forced Expiratory Volume; Humans; Lung; Lung Transplantation; Middle Aged; Pyridones; Tomography, X-Ray Computed; Treatment Outcome	2013
Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases. Archivos de bronconeumologia, 2013, Volume: 49, Issue:8 Topics: Acetylcysteine; Biopsy; Bronchoalveolar Lavage Fluid; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Contraindications; Diagnostic Imaging; Disease Progression; Evidence-Based Medicine; Gastroesophageal Reflux; Genetic Therapy; Glucocorticoids; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Incidence; Indoles; Lung; Lung Transplantation; Oxygen Inhalation Therapy; Palliative Care; Prevalence; Prognosis; Pulmonary Emphysema; Pyridones; Risk Factors; Spain	2013
Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:22 Topics: Acetylcysteine; Administration, Inhalation; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Disease Progression; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2013
NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis. The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:3 Topics: Antineoplastic Agents; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Practice Guidelines as Topic; Product Surveillance, Postmarketing; Pyridones; State Medicine; United Kingdom; Vital Capacity	2013
Management of idiopathic pulmonary fibrosis: selected case reports. European respiratory review : an official journal of the European Respiratory Society, 2014, Volume: 23, Issue:132 Topics: Aged; Anti-Inflammatory Agents; Disease Progression; Fatal Outcome; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Predictive Value of Tests; Pyridones; Recovery of Function; Respiratory Function Tests; Risk Factors; Smoking; Smoking Cessation; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2014
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration; international review of thoracic diseases, 2014, Volume: 88, Issue:3 Topics: Acetylcysteine; Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Expectorants; Fatigue; Female; Gastrointestinal Diseases; Germany; Humans; Idiopathic Pulmonary Fibrosis; Male; Medication Adherence; Middle Aged; Pyridones; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Vital Capacity; Weight Loss	2014
Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surgery today, 2015, Volume: 45, Issue:10 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Disease Progression; Feasibility Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Perioperative Care; Postoperative Complications; Pyridones; Retrospective Studies; Treatment Outcome	2015
Efficacy of combined corticosteroid and pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis after surgery for lung cancer: a case report. Respiratory investigation, 2015, Volume: 53, Issue:1 Topics: Acute-Phase Reaction; Aged, 80 and over; Disease Progression; Drug Therapy, Combination; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Infusions, Intravenous; Lung Neoplasms; Male; Methylprednisolone; Postoperative Complications; Prednisolone; Pulse Therapy, Drug; Pyridones; Treatment Outcome	2015
Update in diffuse parenchymal lung disease, 2013. American journal of respiratory and critical care medicine, 2015, Feb-01, Volume: 191, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Disease Progression; Drug Approval; Enzyme Inhibitors; Genomics; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Diseases, Interstitial; Polymorphism, Genetic; Pyridones; Treatment Outcome; United States; United States Food and Drug Administration	2015
[Two drugs inhibit disease progression. Idiopathic lung fibrosis treatable for the first time]. MMW Fortschritte der Medizin, 2015, Feb-05, Volume: 157, Issue:2 Topics: Acetylcysteine; Disease Progression; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Vital Capacity	2015
A combined therapeutic approach in progressive idiopathic pulmonary fibrosis-pirfenidone as bridge therapy for ex vivo lung transplantation: a case report. Transplantation proceedings, 2015, Volume: 47, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Lung Transplantation; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Quality of Life	2015
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. Respiratory medicine, 2015, Volume: 109, Issue:7 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Italy; Male; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2015
Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT). PloS one, 2015, Volume: 10, Issue:6 Topics: Aged; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Multidetector Computed Tomography; Pyridones; Retrospective Studies; Treatment Outcome	2015
Developments in the management of idiopathic pulmonary fibrosis. Drug and therapeutics bulletin, 2015, Volume: 53, Issue:7 Topics: Disease Progression; Drug Approval; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Orphan Drug Production; Pyridones; United Kingdom	2015
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respiratory investigation, 2015, Volume: 53, Issue:5 Topics: Aged; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Pyridones; Severity of Illness Index; Treatment Outcome; Vital Capacity	2015
Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan. Respiratory investigation, 2015, Volume: 53, Issue:6 Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Multivariate Analysis; Oxygen Consumption; Proportional Hazards Models; Pulmonary Alveoli; Pyridones; Risk Factors; Vital Capacity	2015
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. BMC medicine, 2015, Nov-09, Volume: 13 Topics: Aged; Aged, 80 and over; Biomarkers; Disease Progression; Endothelial Cells; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Vascular Endothelial Growth Factor A	2015
Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:22 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Carbon Monoxide; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Predictive Value of Tests; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity	2015
Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Idiopathic Pulmonary Fibrosis; Japan; Male; Pyridones; Retrospective Studies; Time Factors; Treatment Outcome; Vital Capacity	2016
Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report. BMC pulmonary medicine, 2016, Mar-03, Volume: 16 Topics: Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Pyridones; Tomography, X-Ray Computed; Vital Capacity	2016
Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cough; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity	2016
Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations. Drugs & aging, 2016, Volume: 33, Issue:5 Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Biopsy; Comorbidity; Disease Management; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Incidence; Indoles; Male; Pyridones; Tomography, X-Ray Computed	2016
Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis. The Annals of thoracic surgery, 2016, Volume: 102, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Perioperative Care; Pneumonectomy; Postoperative Complications; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Smoking	2016
Respiratory Conditions Update: Restrictive Lung Disease. FP essentials, 2016, Volume: 448 Topics: Anti-Inflammatory Agents, Non-Steroidal; Continuous Positive Airway Pressure; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Obesity Hypoventilation Syndrome; Oxygen Inhalation Therapy; Polysomnography; Pyridones; Respiratory Function Tests; Respiratory Therapy; Sleep Apnea, Obstructive; Weight Loss	2016
Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Scientific reports, 2016, 09-12, Volume: 6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatomyositis; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Male; Middle Aged; Prospective Studies; Pyridones; Retrospective Studies; Treatment Outcome	2016
Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC pulmonary medicine, 2016, 11-18, Volume: 16, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Belgium; Disease Progression; Female; Graft Survival; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Transplantation; Male; Middle Aged; Postoperative Complications; Pyridones; Retrospective Studies; Tertiary Care Centers; Vital Capacity	2016
3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. JCI insight, 2017, 01-26, Volume: 2, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Case-Control Studies; Disease Progression; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Models, Biological; Myofibroblasts; Precision Medicine; Pyridones; Spheroids, Cellular; Transforming Growth Factor beta1	2017
Guidelines for the medical treatment of idiopathic pulmonary fibrosis. Archivos de bronconeumologia, 2017, Volume: 53, Issue:5 Topics: Adrenal Cortex Hormones; Disease Progression; Disease-Free Survival; Evidence-Based Medicine; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Indoles; Meta-Analysis as Topic; Pulmonary Emphysema; Pyridones; Randomized Controlled Trials as Topic; Societies, Medical; Spain	2017
Renoprotective properties of pirfenidone in subtotally nephrectomized rats. European journal of pharmacology, 2010, Mar-10, Volume: 629, Issue:1-3 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Differentiation; Cell Line; Chronic Disease; Disease Progression; Enalapril; Epithelial Cells; Fibrosis; Kidney; Kidney Failure, Chronic; Male; Mesoderm; Nephrectomy; Proteinuria; Pyridones; Rats; Rats, Wistar; Transforming Growth Factor beta	2010
Trials and tribulations of new agents, novel biomarkers, and retarding renal progression. Journal of the American Society of Nephrology : JASN, 2011, Volume: 22, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Biopsy; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Kidney; Pyridones; Transforming Growth Factor beta	2011
Pirfenidone and chronic progressive obliterative airway disease. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2006, Volume: 25, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Cyclosporine; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Immunosuppressive Agents; Mice; Proteins; Pyridones; Rats	2006